Missouri legislation · 2026 Regular Session
Missouri SB878: Modifies provisions relating to pharmaceutical drugs and devices
Status: Signed into law, August 20, 2026
HCS/SS/SCS/SB 878 - This act modifies provisions relating to pharmaceutical drugs and devices. LIMITS ON SALE OF OVER-THE-COUNTER DRUGS (SECTIONS 195.417 AND 579.060) Currently, no person shall sell, dispense, or purchase, over a 12 month period, more than a total amount of 43.2 grams of certain meth precursors. This act increases the amount to 61.2 grams. Beginning October 1, 2026, any manufacturer of a meth precursor drug that is sold in or into this state shall pay a monthly fee to the administrator of the real-time electronic pseudoephedrine tracking system, as described in the act. The fee is set by the administrator. A manufacturer commits the offense of unlawful, sale, distribution, or purchase of over-the-counter methamphetamine precursor drugs if the manufacturer knowingly fails to pay the fees required by this act. This act is identical to provisions in the perfected HCS/HB 2372 (2026) and substantially similar to provisions in SB 1069 (2026), SB 726 (2025), HB 1036 (2025), provisions of HCS/SS/SB 7 (2025), SCS/SB 317 (2025), SCS/HCS/HB 943 (2025), SB 548 (2025), and SB 143 (2025). PRACTICE OF PHARMACY - VACCINES (SECTION 338.010) Currently, the practice of pharmacy includes the ordering and administration of vaccines approved or authorized by the FDA, but excludes certain vaccines and those vaccines approved after January 1, 2023. This act instead provides that the practice of pharmacy includes the ordering and administration of certain vaccines approved or authorized by the FDA as of January 1, 2026, but excludes certain vaccines and those vaccines approved by the FDA after January 1, 2026, that are not included by joint rules promulgated by the Board of Pharmacy and the State Board of Registration for the Healing Arts. This provision is substantially similar to a provision in the truly agreed to and finally passed HCS/SS#2/SB 1233 (2026), HB 1976 (2026), in the perfected HCS/HB 2372 (2026), and in the perfected HCS/HB 3009 (2
What the bill says
From the enrolled text:
SECOND REGULAR SESSION [TRULY AGREED TO AND FINALLY PASSED] HOUSE COMMITTEE SUBSTITUTE FOR SENATE SUBSTITUTE FOR SENATE COMMITTEE SUBSTITUTE FOR SENATE BILL NO. 103RD GENERAL ASSEMBLY 5598H.07T To repeal sections 195.417, 338.010, 338.012, and 579.060, RSMo, and to enact in lieu thereof ten new sections relating to pharmaceutical drugs and devices, with penalty provisions. Section A. Sections 195.417, 338.010, 338.012, and 579.060, RSMo, are repealed and ten new sections enacted in lieu thereof, to be known as sections 195.417, 338.010, 338.012, 338.206, 338.208, 338.312, 376.417, 376.1280, 376.1960, and 579.060, to read as follows: 195.417. 1. The limits specified in this section shall not apply to any quantity of such product, mixture, or preparation which must be dispensed, sold, or distributed in a pharmacy pursuant to a valid prescription. 2. Within any thirty-day period, no person shall sell, dispense, or otherwise provide to the same individual, and no person shall purchase, receive, or otherwise acquire more than the following amount: any number of packages of any drug product containing any detectable amount of ephedrine, phenylpropanolamine, or pseudoephedrine, or any of their salts or optical isomers, or salts of optical isomers, either as: EXPLANATION-Matter enclosed in bold-faced brackets [thus] in this bill is not enacted and is intended to be omitted in the law. HCS SS SCS SB 878 (1) The sole …